124 related articles for article (PubMed ID: 1980641)
1. Synthesis and biological activity of [MeTyr1,MeArg7,D-Leu8]-dynorphin A(1-9)-NHEt and [D-Cys2-Cys5,MeArg7,D-Leu8]-dynorphin A(1-9)-NH2.
Yoshino H; Arakawa Y; Nakazawa T; Kaneko T; Matsunaga M; Araki S; Ikeda M; Tsuchiya Y; Yamatsu K; Tachibana S
Chem Pharm Bull (Tokyo); 1990 Aug; 38(8):2274-6. PubMed ID: 1980641
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationships of [MeTyr1, MeArg7]-dynorphin A(1-8)-OH analogues with substitution at position 8.
Yoshino H; Kaneko T; Arakawa Y; Nakazawa T; Yamatsu K; Tachibana S
Chem Pharm Bull (Tokyo); 1990 Feb; 38(2):404-6. PubMed ID: 1970951
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships of dynorphin A-(1-8) amide analogues.
Yoshino H; Nakazawa T; Arakawa Y; Kaneko T; Tsuchiya Y; Matsunaga M; Araki S; Ikeda M; Yamatsu K; Tachibana S
J Med Chem; 1990 Jan; 33(1):206-12. PubMed ID: 1967312
[TBL] [Abstract][Full Text] [Related]
4. Design of potent dynorphin A-(1-9) analogues devoid of supraspinal motor effects in mice.
Le HT; Michelot R; Dumont M; Shukla VK; Mayer M; Nguyen KP; Ruan H; Lemaire S
Can J Physiol Pharmacol; 1997 Jan; 75(1):9-14. PubMed ID: 9101059
[TBL] [Abstract][Full Text] [Related]
5. A large-scale synthesis of [MeTyr1, MeArg7, D-Leu8]dynorphin A-(1-8)-NHEt (E-2078) by application of the trifluoroacetic acid-pentamethylbenzene deprotecting procedure in the final stage.
Yoshino H; Tsujii M; Kodama M; Komeda K; Niikawa N; Tanase T; Asakawa N; Nose K; Yamatsu K
Chem Pharm Bull (Tokyo); 1990 Jun; 38(6):1735-7. PubMed ID: 1976444
[No Abstract] [Full Text] [Related]
6. Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
Kawasaki AM; Knapp RJ; Kramer TH; Walton A; Wire WS; Hashimoto S; Yamamura HI; Porreca F; Burks TF; Hruby VJ
J Med Chem; 1993 Mar; 36(6):750-7. PubMed ID: 8096246
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of highly potent and selective cyclic dynorphin A analogues.
Kawasaki AM; Knapp RJ; Kramer TH; Wire WS; Vasquez OS; Yamamura HI; Burks TF; Hruby VJ
J Med Chem; 1990 Jul; 33(7):1874-9. PubMed ID: 1972964
[TBL] [Abstract][Full Text] [Related]
8. Effects of modifications of residues in position 3 of dynorphin A(1-11)-NH2 on kappa receptor selectivity and potency.
Lung FD; Meyer JP; Lou BS; Xiang L; Li G; Davis P; DeLeon IA; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 1996 Jun; 39(13):2456-60. PubMed ID: 8691442
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological properties of highly potent cyclic dynorphin A analogues. Analogues cyclized between positions 5 and 11.
Meyer JP; Collins N; Lung FD; Davis P; Zalewska T; Porreca F; Yamamura HI; Hruby VJ
J Med Chem; 1994 Nov; 37(23):3910-7. PubMed ID: 7966152
[TBL] [Abstract][Full Text] [Related]
10. [2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.
Lu Y; Nguyen TM; Weltrowska G; Berezowska I; Lemieux C; Chung NN; Schiller PW
J Med Chem; 2001 Sep; 44(19):3048-53. PubMed ID: 11543672
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and opioid activity of 2-substituted dynorphin A-(1-13) amide analogues.
Story SC; Murray TF; Delander GE; Aldrich JV
Int J Pept Protein Res; 1992 Aug; 40(2):89-96. PubMed ID: 1359999
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2.
Lung FD; Collins N; Stropova D; Davis P; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 1996 Mar; 39(5):1136-41. PubMed ID: 8676350
[TBL] [Abstract][Full Text] [Related]
13. Rational design of dynorphin A analogues with delta-receptor selectivity and antagonism for delta- and kappa-receptors.
Guerrini R; Capasso A; Marastoni M; Bryant SD; Cooper PS; Lazarus LH; Temussi PA; Salvadori S
Bioorg Med Chem; 1998 Jan; 6(1):57-62. PubMed ID: 9502105
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 1. Conformational constraint in the "message" sequence.
Arttamangkul S; Murray TF; DeLander GE; Aldrich JV
J Med Chem; 1995 Jun; 38(13):2410-7. PubMed ID: 7608905
[TBL] [Abstract][Full Text] [Related]
15. Design of potent and selective dynorphin A related peptides devoid of supraspinal motor effects in mice.
Shukla VK; Lemaire S; Ibrahim IH; Cyr TD; Chen Y; Michelot R
Can J Physiol Pharmacol; 1993; 71(3-4):211-6. PubMed ID: 8104674
[TBL] [Abstract][Full Text] [Related]
16. N,N-diallyl-tyrosyl substitution confers antagonist properties on the kappa-selective opioid peptide [D-Pro10]dynorphin A(1-11).
Gairin JE; Mazarguil H; Alvinerie P; Botanch C; Cros J; Meunier JC
Br J Pharmacol; 1988 Dec; 95(4):1023-30. PubMed ID: 2905908
[TBL] [Abstract][Full Text] [Related]
17. Effect of modification of the basic residues of dynorphin A-(1-13) amide on kappa opioid receptor selectivity and opioid activity.
Snyder KR; Story SC; Heidt ME; Murray TF; DeLander GE; Aldrich JV
J Med Chem; 1992 Nov; 35(23):4330-3. PubMed ID: 1360025
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
Vig BS; Murray TF; Aldrich JV
J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314
[TBL] [Abstract][Full Text] [Related]
19. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
Vig BS; Zheng MQ; Murray TF; Aldrich JV
J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological activity of dynorphin-(1-13) and analogs substituted in positions 8 and 10.
Lemaire S; Lafrance L; Dumont M
Int J Pept Protein Res; 1986 Mar; 27(3):300-5. PubMed ID: 2872177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
